ArticleGates open research2022

An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of

Alejandro Krolewiecki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.